Catalog No.
VMC83401
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Target
Bispecific, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, Cd274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, T-cell-specific surface glycoprotein CD28, CD28, Cd28
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9EP73 & P31041
Applications
FuncS
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0245
Development of a prognostic immune cell-based model for ovarian cancer using multiplex immunofluorescence., PMID:40537823
Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort., PMID:40537320
Xeno-free alternatives to the use of fetal bovine serum in head and neck cancer explant culture., PMID:40537045
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609
Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473
Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)., PMID:40535732
First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis., PMID:40535117
Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations., PMID:40535092
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression., PMID:40535088
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy., PMID:40535067
F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867
Janus kinase and signal transducer and activator of transcription inhibitors in type 1 diabetes and immune checkpoint-related diabetes: current status and future perspectives., PMID:40534861
Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients., PMID:40534853
A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a/PD-L1 signaling in gastric cancer immunotherapy resistance., PMID:40534828
The PD-1/PD-L1 pathway and Epstein-Barr virus., PMID:40533842
Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort., PMID:40533655
PDHA1 Orchestrates Hepatocellular Carcinoma Progression Through LINC00607-Mediated Regulation of Cuproptosis and Immune Evasion., PMID:40533619
Proteasome Inhibition Induces IRF1 Downstream Molecules Independently of JAK Activity in Cancers., PMID:40533173
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data., PMID:40532262
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer., PMID:40532178
Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion., PMID:40532063
[Another sight at Gastric Cancer Molecular Classification: novel subtypes based on expression of CDX-2, E-cadherin, Epstein-Barr virus RNAs, MMR proteins]., PMID:40531557
Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis., PMID:40531080
Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers., PMID:40530506
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death., PMID:40530421
Therapeutic potential of adenosine receptor modulators in cancer treatment., PMID:40530308
Prognostic value of lactate dehydrogenase to albumin ratio in first-line chemoimmunotherapy for locally advanced or metastatic non-small cell lung cancer., PMID:40530119
Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study., PMID:40529756
Integrated pan-cancer analysis of ADM's role in prognosis, immune modulation and resistance., PMID:40529377
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging., PMID:40529364
Site-Selective Anti-PD-L1 Antibody-MMAE Conjugate for Enhanced NSCLC Therapy., PMID:40529092
Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy., PMID:40528544
HAPIR: a refined Hallmark gene set-based machine learning approach for predicting immunotherapy response in cancer patients., PMID:40527973
LASIP: Light-Activated STING Immunotherapeutic Patch: A Multifunctional Microneedle Platform for Combinatorial Mild Hyperthermia with Immunotherapy in Breast Cancer., PMID:40527606
Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation., PMID:40527320
Multifunctional Nanoplatform for Highly Accurate Profiling of Triple-Negative Breast Cancer-Derived Chemo- and Immunotherapy Resistance Exosomes., PMID:40526975
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia., PMID:40526840
Precise PEGylation Modulates the in Vivo Fate of Peptide Radiopharmaceuticals., PMID:40525701
An Anisotropic Gold-Palladium Heterostructured Nanosystem for Synergistically Overcoming Radioresistance and Enhancing Melanoma Radioimmunotherapy., PMID:40525676
Engineering TLR7/8 Agonist-Loaded and Tumor-Anchored Gold Nanosensitizers for Enhanced Radioimmunotherapy., PMID:40525673
A Multimodal Nanoplatform Integrating Photodynamic Therapy and Wnt/β-Catenin Inhibition Reprograms the Tumor Microenvironment to Potentiate Immune Checkpoint Therapy in Triple-Negative Breast Cancer., PMID:40525603
Systematic Pan-Cancer Analysis of the Oncogenic and Immunological Function of Stanniocalcin-1 (STC1)., PMID:40525442
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial., PMID:40524802
Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study., PMID:40524516
An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2+ overload triggered pyroptosis., PMID:40524159
For research use only. Not for human or drug use.
